Season 5, Post 16: Happy Birthday HGP
Twenty years ago this month a quite revolutionary announcement was made. Scientists confirmed that they had a finished sequence of DNA which covered 99% of the human genome and was 99.99% accurate. Although many (including your author) probably did not pay too much attention at the time, the legacy of the Human Genome Project (or HGP) is both significant and enduring.
In 2003, had any scientific or medical researcher wanted to sequence genomic data, it would have cost $100m and taken almost a week to complete the work for a single run. As in many other fields, the impact of scale economics combined with Moore’s Law mean that today it is possible to sequence DNA for well below $1000. Some of the most advanced sequencing machines available today (made by Oxford Nanopore, for example – whom we are visiting in May) do not even need to break DNA into fragments – as was the case historically – but rather pull entire chromosome strands through a molecular pore just a few nanometres in diameter. The bases of the strand are read as they pass through the pore, yielding results in just minutes.
We first discussed the potential for sequencing over a decade ago. Put simply, think of biology as a data service. Understand the genome and medicine can move from being reactive to pre-emptive. Know your DNA and it could be possible to predict certain future illnesses, hereditary traits and how the body might respond to certain treatments. Genetics will increasingly inform doctors’ decisions. In many countries (such as the UK ), DNA screening is now occurring from birth. Bigger databases imply better outcomes.
No part of biology has remained untouched. If you can sequence human genomes, then why not those of animals or plants too? Given that arguably the largest challenge facing the world is how to allocate scarce resources efficiently in the face of a growing population, understanding how to make crops more resilient could, for example, prove to be a game-changer. With progress, of course, comes consequences. As multiomics (the top-down discipline of looking at the genome) becomes more embedded, considerations about genetic engineering will increasingly come to the fore. Further, as biology becomes much more of a big data exercise, then the data will have to be secured, for otherwise they have no value. Even at twenty, the full significance of the HGP is only just beginning to emerge.
26 April 2023
The above does not constitute investment advice and is the sole opinion of the author at the time of publication. Past performance is no guide to future performance and the value of investments and income from them can fall as well as rise.
Click here to view all Blog posts.
Alex Gunz, Fund Manager
Disclaimers
The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital LLP believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital LLP, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital LLP is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital LLP disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document.
The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital LLP’s prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital LLP’s prior written consent.
Heptagon Capital LLP, 63 Brook Street, Mayfair, London W1K 4HS
tel +44 20 7070 1800
email [email protected]
Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority
Heptagon Capital Limited is licenced to conduct investment services by the Malta Financial Services Authority.
